Lawyers wrapping up the final details of a $200 million California class action settlement over hormone replacement therapy drugs have found a novel solution for a nice problem to have: what to do with all the leftover money.

Even after the standard 25% in attorney fees—about $50 million—and more than $1 million in expenses and notice costs, the settlement with the now-defunct Wyeth Inc., which made Premarin, Prempro and Premphase, leaves about $142 million in residual funds, according to the lawyers. Starting next year, that money will go to research and education to promote women’s health.